KR20250052493A - 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 - Google Patents

인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 Download PDF

Info

Publication number
KR20250052493A
KR20250052493A KR1020257011427A KR20257011427A KR20250052493A KR 20250052493 A KR20250052493 A KR 20250052493A KR 1020257011427 A KR1020257011427 A KR 1020257011427A KR 20257011427 A KR20257011427 A KR 20257011427A KR 20250052493 A KR20250052493 A KR 20250052493A
Authority
KR
South Korea
Prior art keywords
patients
antibody
seq
cxcr5
sar113244
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257011427A
Other languages
English (en)
Korean (ko)
Inventor
제프리 밍
모셰 이. 질버스테인
로지에 카리미 안더레시
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of KR20250052493A publication Critical patent/KR20250052493A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020257011427A 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료 Pending KR20250052493A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
KR1020197030748A KR20190131068A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030748A Division KR20190131068A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Publications (1)

Publication Number Publication Date
KR20250052493A true KR20250052493A (ko) 2025-04-18

Family

ID=61827719

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257011427A Pending KR20250052493A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료
KR1020197030748A Ceased KR20190131068A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197030748A Ceased KR20190131068A (ko) 2017-03-22 2018-03-22 인간화된 항-cxcr5 항체를 사용하는 루푸스의 치료

Country Status (7)

Country Link
US (1) US20240207397A1 (cg-RX-API-DMAC7.html)
EP (1) EP3601344A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020514386A (cg-RX-API-DMAC7.html)
KR (2) KR20250052493A (cg-RX-API-DMAC7.html)
CN (1) CN110662767A (cg-RX-API-DMAC7.html)
AU (1) AU2018238540B2 (cg-RX-API-DMAC7.html)
IL (2) IL318907A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
KR20230004472A (ko) * 2020-04-21 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 인간화 cxcl13 유전자를 갖는 비인간 동물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2195023B1 (en) * 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
MX2017002381A (es) * 2014-08-22 2017-09-15 Sorrento Therapeutics Inc Proteinas de union de antigeno que se unen a cxcr5.

Also Published As

Publication number Publication date
AU2018238540B2 (en) 2025-02-27
US20240207397A1 (en) 2024-06-27
EP3601344A1 (en) 2020-02-05
JP2020514386A (ja) 2020-05-21
IL269419A (en) 2019-11-28
KR20190131068A (ko) 2019-11-25
AU2018238540A1 (en) 2019-11-07
JP2025087764A (ja) 2025-06-10
CN110662767A (zh) 2020-01-07
IL318907A (en) 2025-04-01
JP2023040241A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
JP5926162B2 (ja) 炎症傷害の処置および評価
JP6515168B2 (ja) Il−17アンタゴニストを用いて関節リウマチを治療する方法
AU2007327993B2 (en) Methods of treating systemic lupus erythematosus
EP3237447B1 (en) Anti-csf1r antibodies for treating pvns
US20210403587A1 (en) Methods of treating multiple myeloma
TWI670077B (zh) 使用pcsk9抑制劑之給藥療程
JP2008544960A5 (cg-RX-API-DMAC7.html)
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
TW202332696A (zh) 治療發炎症狀的方法
CN113573732A (zh) TACI-Fc融合蛋白及其用途
RS57543B1 (sr) Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
CN113301955A (zh) 治疗掌跖脓疱症的抗il-36r抗体
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
JP2025087764A (ja) ヒト化抗cxcr5抗体を使用するループスの処置
JP2025000638A (ja) 抗IFN-α/ω抗体の投与方法
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20230203149A1 (en) Treatment of atopic dermatitis
CN115066272A (zh) Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
WO2016118921A1 (en) Compositions and methods for treating psoriatic arthritis
CN121909046A (zh) 脱发病症的治疗
AU2023338115A1 (en) Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250408

Application number text: 1020197030748

Filing date: 20191018

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250508

Comment text: Request for Examination of Application